Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000573847 | SCV000670770 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-03 | criteria provided, single submitter | clinical testing | The p.T277M variant (also known as c.830C>T), located in coding exon 8 of the PMS2 gene, results from a C to T substitution at nucleotide position 830. The threonine at codon 277 is replaced by methionine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000587439 | SCV000697390 | uncertain significance | not specified | 2020-07-08 | criteria provided, single submitter | clinical testing | Variant summary: PMS2 c.830C>T (p.Thr277Met) results in a non-conservative amino acid change located in the N-terminal (IPR002099) domain and S5 domain 2-like (IPR013507) domain of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251422 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.830C>T in individuals affected with Hereditary Nonpolyposis Colorectal Cancer and no experimental evidence demonstrating its impact on protein function have been reported. Three ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Color Diagnostics, |
RCV000573847 | SCV000904181 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-01-07 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with methionine at codon 277 of the PMS2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 9/282828 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Labcorp Genetics |
RCV001049150 | SCV001213184 | likely benign | Hereditary nonpolyposis colorectal neoplasms | 2024-08-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001553488 | SCV001774368 | uncertain significance | not provided | 2019-09-18 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001553488 | SCV002774696 | uncertain significance | not provided | 2021-07-27 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV004001071 | SCV004839905 | uncertain significance | Lynch syndrome | 2024-09-23 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with methionine at codon 277 of the PMS2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 9/282828 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |